CAL-101 (Idelalisib, GS-1101)

CAL-101 (Idelalisib, GS-1101) is an inhibitor for PI3Kδ/P110δ. This product is provided as 10 mg of dry powder.

Catalog #: 92-1258 Size: 10 mg


Biological Information
Background Information:
CAL-101 (Idelalisib, GS-1101, Zydelig) is a synthetic drug that potently inhibits the phosphoinositide 3-kinase P110δ(PI3Kδ) (IC50=2.5nM), with 40-300-fold selectivity over p110α, β, and γ. CAL-101 is FDA approved for treatment of chronic lymphocytic leukemia (CLL) in combination with rituximab. Provided as 10 mg of dry powder.
Target Name:
Product Type:
Control Ligands & Inhibitors
Drug Discovery & Development
Storage Conditions:
Store at -20°C. Please avoid multiple freeze/thaw cycles.
Usage Disclaimer:
These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit for a list of products that are governed by limited use label license terms and relevant patent and trademark information.
Additional Information


92-1258 Datasheet

View Document